This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Exosome Presents Late-Breaking Study Demonstrating Ability To Profile RNA From Archived Clinical Trial Blood Samples At 2013 American Association Of Cancer Research Annual Meeting

NEW YORK, April 8, 2013 /PRNewswire/ -- Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostics for use in personalized medicine, today announced that the company is presenting a late-breaking abstract at the AACR Annual Meeting 2013, in Washington D.C.  The abstract is titled "Exosome profiling of mRNAs and miRNAs in serum samples from GBM (glioblastoma multiforme) patients." It will be presented during Poster Session 47 from 1 to 5 p.m. EDT on April 8 by Johan Skog, Ph.D., the newly appointed chief scientific officer of Exosome Diagnostics.   

In this study, Exosome Diagnostics used its proprietary RNA-extraction technology to measure a broad spectrum of full-length mRNA and microRNA from low volumes (2 mL) of frozen, archival serum from brain cancer patients enrolled in a therapeutic clinical trial.  Prior to the introduction of Exosome Diagnostics' technology, similar biomarker analysis would have required performing invasive brain tissue biopsies.

This clinical study represents the third biofluid in which Exosome Diagnostics has demonstrated the ability to harvest disease-specific RNA biomarkers.  Data have been presented in clinical studies from different disease groups from urine, blood, and cerebrospinal fluid exosome preparations.

"Extraction of high-quality RNA, particularly intact messenger RNA, from blood, urine or CSF samples is an important advance for discovering and measuring both known and novel biomarkers for patient selection and drug response," said Johan Skog, Ph.D.  "This study demonstrates that frozen and archived biofluid samples can be interrogated for gene expression along with fresh samples in patient populations of interest to clinical investigators and drug developers."

James McCullough, chief executive officer of Exosome said, "Rapid, reproducible extraction of high quality RNA with appropriate internal quality control from frozen blood samples satisfies an important request from our pharmaceutical partners to unlock the potential of their vast clinical trial bio-banks.  We are now firming plans to launch an Exosome Diagnostics life sciences kit product line in early 2014 to enable drug developers and researchers to pursue biomarker discovery in cancer, CNS and other diseases."   

Exosomes are microscopic packages shed by all cells into biofluids such as blood, urine and cerebrospinal fluid.  Exosomes protect an abundance of active genetic material (ribonucleic acid or "RNA") that, when properly harvested, can produce accurate molecular diagnostic measurements using standard PCR and sequencing instruments.  In addition to its planned life science product line, Exosome Diagnostics has been conducing multi-center clinical validation studies in partnership with the Prostate Cancer Foundation for the first-ever regulated exosome in vitro diagnostic, which targets early stage prostate cancer from a random patient urine sample. 

About Exosome DiagnosticsExosome Diagnostics is a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes are shed into all biofluids, including blood, urine and CSF, providing a stable source for intact, cell-specific nucleic acids. The Company's proprietary exosome technology makes use of the presence and natural stability of RNA in exosomes to detect and measure levels of genes responsible for cancer and other diseases. The Company is developing in vitro diagnostic tests for use in companion diagnostic applications and real-time monitoring of disease. For more information, please visit www.exosomedx.com.

SOURCE Exosome Diagnostics

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,690.66 -55.32 -0.31%
S&P 500 2,102.54 -6.09 -0.29%
NASDAQ 5,125.09 -3.6950 -0.07%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs